PDCD1 and skin squamous cell carcinoma: The ENLIGHT-DP biomarker, derived from transcriptomic analysis of Hematoxylin and Eosin slides, has shown promise in predicting response to PD-1 inhibition in advanced cSCC, including in patients previously treated with surgery or radiotherapy, but it has not been validated for routine use [29].